Results grounded in experimental dataβnot abstracts.
Press Enter β΅ to solve
Fuel Your Discoveries
"The first principle is that you must not fool yourself β and you are the easiest person to fool."
- Richard Feynman
Quick Explanation
Copied
The provided βBest Evidence: HSP60 Inhibitors and Selectivity Evidence (ATPase HSP10 PPI Cys442)β is **not supported** by the supplied raw research inputs: the included papers focus on **HSP60βsubstrate interactions, HSP60 chaperone roles, and HSP60-dependent signaling/pathway phenotypes**, but **do not report the specific inhibitor class/targeting mode (ATPase activity, HSP10βHSP60 PPI disruption, or Cys442 selectivity)** needed to substantiate the claim.
Long Explanation
HSP60 Inhibitors & βSelectivity Evidenceβ β Evidence Battle-Test (based on supplied raw inputs)
Critical finding (data-mismatch):
The supplied corpus does not contain the inhibitor-specific experiments needed to justify the claim βATPase / HSP10 PPI / Cys442 selectivity.β Instead, it contains diverse functional biology of HSP60 (chaperone substitution, interaction partners, compartment roles, immune signaling, and phenotypes from HSP60 level perturbations).
1) What the provided evidence actually covers (evidence-type map)
Paper (DOI)
HSP60 role tested
Has inhibitor selectivity? (ATPase / HSP10 PPI / Cys442)
Primary evidence mode
Main limitations relevant to βinhibitor selectivityβ claim
HSP60 interacts with HIV-1 integrase (two systems)
No
IN-stage-specific functional assays
Still not inhibitor/cys442/selectivity.
2) Visual evidence: where the numbers are (HIV-1 integrase stage readouts)
The only supplied numeric fold-change data that is directly βHSP60 perturbation β viral step outcomeβ (and thus closest to βinhibitor logic,β though still not inhibitor selectivity) is from the Hsp60/SAHH HIV-1 early replication paper excerpt.
Source of the numeric fold-changes:
3) Why this does not establish βHSP60 inhibitor selectivityβ (ATPase / HSP10 PPI / Cys442)
Target mismatch: None of the supplied inputs explicitly evaluates HSP60 inhibitors, nor demonstrates selectivity via ATPase mechanism, HSP10 PPI disruption, or Cys442 engagement.
Readout mismatch: Many studies test chaperone function, interaction partners, or signaling phenotypes rather than direct inhibitory mechanism and off-target selectivity.
Species/protein-context mismatch: Several inputs are bacteria/yeast/plants/immune signaling models, where βHSP60β may not have identical residues or inhibitor-binding conformations.
Mechanistic ambiguity: Even when ATP (or ATP-related effects) are used experimentally, that does not equal βinhibitor selectivityβ without structure-informed binding/kinetics or residue-specific chemistry.
4) What would be needed to substantiate the original βBest Evidenceβ claim (mechanism-grade check)
Checklist (evidence thatβs missing from supplied inputs)
To credibly claim βHSP60 inhibitorsβ with βselectivity evidenceβ tied to ATPase, HSP10 PPI, or Cys442, the raw inputs must include (at minimum):
Biochemical assays showing direct inhibition of HSP60 ATPase and kinetic parameters (and controls for ATPase-independent effects).
HSP10βHSP60 PPI disruption assays with binding/complex readouts (e.g., complex stability, co-immunoprecipitation, or biophysics).
Residue-level evidence for Cys442 (chemistry adducts, mutagenesis swapping Cys442 context, or binding-site validation).
Cross-protein selectivity profiling (other chaperones, paralogs) and orthogonal cellular phenotypes.
Species-matched relevance (human vs microbial systems) or explicit comparability justification.
5) βClosest-supportβ mechanistic breadcrumbs present in the supplied inputs (but still not selectivity)
Breadcrumb A β Functional coupling of Hsp60 with Hsp10 and ATP dependence exists as biology
The maize mitochondrial paper shows that hsp60 associations with newly synthesized F1-ATPase alpha subunits are disrupted by Mg-ATP, implying ATP-linked disassembly dynamics. This is mechanistically relevant to ATPase-related biology, but it is not an inhibitor Cys442/HSP10-PPI selectivity experiment.
Breadcrumb B β Hsp60/Hsp10 can affect ATPase activity and client functional outcomes (HIV integrase example)
In the HIV-1 integrase study, the Hsp60βHsp10 complex exhibits ATPase activity in the presence of IN and stimulates IN functions; however, the supplied evidence excerpt does not introduce an Hsp60 inhibitor or residue-specific selectivity claims.
Breadcrumb C β HSP60 modulates biological pathways that could be pharmacologically relevant (immune axis)
The PRMT3βHSP60 R446 methylation work shows that HSP60 modifications influence mitochondrial homeostasis and cGAS/STING signaling. But the therapeutic perturbation in the excerpt targets PRMT3 (with an inhibitor), not HSP60 directly.
6) Bottom-line verdict on the provided βBest Evidenceβ
Verdict: With the supplied raw inputs, the label βHSP60 Inhibitors and Selectivity Evidence (ATPase / HSP10 PPI / Cys442)β is unsupported. The evidence supports HSP60 functional importance and diverse HSP60-dependent mechanisms, but it does not validate the inhibitor-selectivity mechanism implied by βATPase / HSP10 PPI / Cys442.β
7) What information would most likely disprove this conclusion
If you provide the missing raw paper(s) that directly test HSP60 inhibitors and include residue-/mechanism-level selectivity (especially around Cys442, ATPase kinetics, and HSP10βHSP60 PPI disruption), then this mismatch could be corrected. Without those, the current dataset cannot substantiate the original selection-criteria wording.
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
Assuming inhibitor selectivity can be inferred from HSP60 perturbation phenotypes alone: without direct inhibition/complex-disruption assays and residue-level validation, this inference is likely weak.
Assuming ATP dependence in chaperone biology automatically implies ATPase inhibitorsβ selectivity: Mg-ATP dissociation dynamics do not establish inhibitor engagement or selectivity at the residue/mechanism level.
Quick Explanation
Long Explanation
Top Data Sources
ExportMCP
Keep Exploring
Hypothesis Graveyard
Potential Experiments
Discussion
Fuel Your Discoveries
Ask a Follow-Up
Key Insight
